Survival after second primary lung cancer
Open Access
Abstract
BACKGROUND: Lung cancer accounts for the largest absolute risk of second malignancies among Hodgkin lymphoma (HL) survivors. However, no population‐based studies have compared overall survival (OS) between HL survivors who developed nonsmall cell lung cancer (HL‐NSCLC) versus patients with first primary NSCLC (NSCLC‐1).METHODS: The authors compared the OS of 178,431 patients who had NSCLC‐1 and 187 patients who had HL‐NSCLC (among 22,648 HL survivors), accounting for sex, race, sociodemographic status, calendar year, and age at NSCLC diagnosis, and NSCLC histology and stage. All patients were reported to the population‐based Surveillance, Epidemiology, and End Results Program. Hazard ratios (HRs) were derived from a Cox proportional hazards model.RESULTS: Although the NSCLC stage distribution was similar in both groups (20% localized, 30% regional, and 50% distant), HL survivors experienced significantly inferior stage‐specific OS. For patients with localized, regional, and distant stage NSCLC, the HRs (95% confidence interval [CI]) for death among HL survivors were 1.60 (95% CI, 1.08‐2.37; P < .0001), 1.67 (95% CI, 1.26‐2.22; P = .0004), and 1.31 (95% CI, 1.06‐1.61; P = .013), respectively. Among HL‐NSCLC patients, significant associations were observed between more advanced NSCLC stage and the following variables: younger age at HL diagnosis (P = .003), younger age at NSCLC diagnosis (P = .048), and longer latency between HL and NSCLC diagnoses (P = .015).CONCLUSIONS: Compared with patients who had de novo NSCLC, HL survivors experienced a significant 30% to 60% decrease in OS after an NSCLC diagnosis. Further research is needed to not only elucidate the clinical‐biologic underpinnings of NSCLC after HL, including the influence of previous HL treatment, but also to define the role of lung cancer screening in selected patients. Cancer 2011;. © 2011 American Cancer Society.Keywords
This publication has 31 references indexed in Scilit:
- Clinical course of thoracic cancers in Hodgkin's disease survivorsAnnals of Oncology, 2005
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003
- Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood, 2002
- Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 YearsJournal of Clinical Oncology, 2002
- The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin diseaseCancer, 2002
- Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's DiseaseJNCI: Journal of the National Cancer Institute, 2002
- Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young AdulthoodJournal of Clinical Oncology, 2000
- Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at TreatmentJournal of Clinical Oncology, 2000
- Lung Cancer After Hodgkin's DiseaseJNCI: Journal of the National Cancer Institute, 1995
- Second cancer risk following Hodgkin's disease: a 20-year follow-up study.Journal of Clinical Oncology, 1994